Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Want to cut your energy bills? Here’s how five experts are doing it 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
ANN ARBOR, Mich., March 08, 2016 -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C, today announced Tim M. Mayleben, president and chief executive officer, will present at the Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 15, 2016 at 8:30 A.M. Eastern Time.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients by developing therapies to lower elevated LDL-C. Esperion scientists discovered bempedoic acid and the LDL-C lowering therapy is in late stage development. Esperion plans to develop both bempedoic acid and a fixed-dose combination of bempedoic acid and ezetimibe with a particular focus on patients with elevated LDL-C who are considered intolerant of statin therapy. It is estimated that approximately 10% of patients who are prescribed statins, 3.5 million patients in the U.S., are considered statin intolerant.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-C lowering therapies for the treatment of patients with elevated LDL-C. Bempedoic acid, the Company’s lead product candidate, is an inhibitor of ATP Citrate Lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors, resulting in increased LDL-C clearance and reduced plasma levels of LDL-C. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact: Elliot Fox W2O Group 212.257.6724 [email protected] Investor Contact: Mindy Lowe Esperion Therapeutics 734.887.3903 [email protected]
